MEK wars, a new front in the battle against cancer

Nature Medicine

Volumn 5, Issue 7, 1999, Pages 736-737

  Duesbery, Nicholas S ^a   Webb, Craig P ^b   Vande Woude, George F ^c  

^a Van Andel Research Center   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE;

CANCER; CANCER INHIBITION; ENZYME INHIBITION; GENE CONTROL; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0033021061     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/10457     Document Type: Short Survey

References (14)

1. Sebolt-Leopold, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 5, 810-816 (1999).
2. Lewis, T.S., Shapiro, P.S. & Ahn, N.G. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74, 49-139 (1998).
3. Cowley, S., Paterson, H., Kemp, P. & Marshall, C.J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77, 841-852 (1994).
4. Mansour, S.J. et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265, 966-970 (1994).
5. Webb, C.P., Van Aelst, L., Wigler, M.H. & Vande Woude G.F. Signaling pathways in ras-mediated tumorigenicity and metastasis. Proc. Natl. Acad. Sci. USA 95, 8773-8778 (1998).
6. Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J. & Saltiel, A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92, 7686-7689 (1995).
7. Okazaki, K. & Sagata, N. MAP kinase activation is essential for oncogenic transformation of NIH3T3 cells by Mos. Oncogene 10, 1149-1157 (1995).
8. Nishio, K. et al. Mitogen-activated protein kinase anti-sense oligonucleotide inhibits the growth of human lung cancer cells. Int. J. Oncol. 14, 461-469 (1999).
9. Duesbery, N. and Vande Woude, G.F. Anthrax lethal factor causes proteolytic inactivation of MAP-Kinase-Kinase. Lett. Appl. Microbiol. (in the press 1999).
10. Hoshino, R. et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813-822 (1999).
11. Salh, B. et al. Differential cyclin-dependent kinase expression and activation in human colon cancer. Anticancer Res. 19, 741-748 (1999).
12. Sivaraman, V.S., Wang, H., Nuovo, G.J., & Malbon, C.C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 99, 1478-1483 (1997).
13. Mandell, J.W., Hussaini, I.M., Zecevic, M., Weber, M.J. & Vandenberg, S.R. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am. J. Pathol. 153, 1411-1423 (1998).
14. Duesbery, N.S. et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280, 734-737 (1998).